Missouri · 2026 Regular Session · Bill
HB 2081: Creates provisions relating to reporting requirements for entities that participate in the 340B drug pricing program
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
HB 2081 is a bill introduced in the Missouri House on December 1, 2025. According to its official title, it concerns: Creates provisions relating to reporting requirements for entities that participate in the 340B drug pricing program. Primary sponsor: Ben Keathley (Republican). It lists 1 additional sponsor. Most recent recorded action (May 15, 2026): Referred: Emerging Issues(H).
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Sponsors
Sponsors by party (alphabetical): Republican 2
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Ben Keathley | Primary sponsor | Republican | House | 101 |
| Bob Titus | Co-sponsor | Republican | House | 139 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- Referred: Emerging Issues(H)
- Read Second Time (H)
- Read First Time (H)
- Prefiled (H)